Two mAbs against MUC16, oregovomab and abagovomab, have been trialled separately in phase III clinical trials in patients with ovarian cancer, but neither showed significantly improved clinical outcomes compared to controls [365]. The gene discussed is MUC16; the disease is ovarian cancer.